

Figure S1. Overall survival in patients with lung recurrences based on bilateral versus unilateral metastases (P=0.13)




Table S1. Clinical characteristics of patients presenting with abdominal/pelvic recurrences (n=29)

Variable	N (%)
Median age at diagnosis (years)	
Median (range)	57 (34-71)
FIGO Stage at diagnosis	
1	19 (65.5)
2	6 (20.7)
3	1 (3.4)
4	3 (10.3)
Adjuvant chemotherapy following primary surgery	10 (34)
Doxorubicin/Ifosfamide	1 (10)
Gemcitabine	1 (10)
Gemcitabine/Docetaxel	6 (60)
Gemcitabine/Docetaxel/Doxorubicin	1 (10)
Cisplatin/Paclitaxel	1 (10)
Adjuvant radiation following primary surgery	4 (14)
Whole Pelvic	3 (75)
Whole Pelvic + Intravaginal	1 (25)
Hormonal therapy following primary surgery	2 (6.9)
Aromatase Inhibitor	2 (100)
Median time to recurrence (months)	
Median (95% CI)	15.8 (13.0 – 18.6)
Median age at recurrence (range)	58.4 (35.2-75.2)
Residual at recurrence surgery	
None	26 (89.7)
Gross	
<1cm	1 (3.4)
≥1cm	2 (6.9)
Chemotherapy following recurrence surgery	7 (24)

Doxorubicin/Ifosfamide	4 (57)
Gemcitabine	2 (28)
Gemcitabine/Docetaxel	1 (14)
Adjuvant radiation following recurrence surgery	9 (31)
Whole Pelvic	9 (100)
Hormonal therapy following recurrence surgery	5 (17)
Aromatase Inhibitor	4 (80)
Selective Estrogen Receptor Modulators	1 (20)
Overall Survival	
Median (95% CI)	37.7 (25.9-49.6)
Dead of Disease	23 (79.3)

Table S2. Clinical characteristics of patients presenting with lung recurrences (n=30)

Variable	N (%)
Median age at diagnosis (years)	
Median (range)	53 (36-74)
FIGO Stage at Diagnosis	
1	24 (77.4)
2	1 (6.4)
3	1 (3.2)
4	1 (3.2)
N/A	3 (9.7)
Adjuvant chemotherapy following primary surgery	9 (30)
Doxorubicin	1 (11)
Gemcitabine/Docetaxel or Paclitaxel	4 (44)
Gemcitabine/Docetaxel/Doxorubicin	1 (11)
Cisplatin/Ifosfamide	1 (11)
N/A	2 (22)
Adjuvant radiation following primary surgery	3 (10)
Whole Pelvic	3 (100)
Hormonal therapy following primary surgery	0 (0)
Median time to recurrence (months)	
Median (95% CI)	24.1 (14.5-33.7)
Median age at recurrence (range)	56.4 (40.9-76.9)
Lesion site	
Unilateral	24 (80)
Bilateral	6 (20)
Residual at recurrence surgery	
None	30 (96.8)
Gross	
<1cm	0 (0)
≥1cm	0 (0)

Chemotherapy following recurrence surgery	3 (10)
Gemcitabine/Docetaxel or Paclitaxel	2 (66)
Mesna, Doxorubicin, Ifosfamide, Dacarbazine	1 (33)
Radiation following recurrence surgery	1 (3)
External Beam	1 (100)
Hormonal therapy following recurrence surgery	5 (16.7)
Aromatase Inhibitor	3 (60)
Selective Estrogen Receptor Modulators	0 (0)
Progesterone	2 (40)
Overall Survival (months)	
Median (95% CI)	78.1 (44.8-111.4)
Dead of Disease	20 (66)

Table S3. Clinical characteristics of patients presenting with abdominal/pelvic and lung recurrences (n=3)

Variable	N (%)
Median age at diagnosis (years)	
Median (range)	47.0 (32-51)
FIGO Stage at diagnosis	
1	3 (75.0)
2	0
3	0
4	0
Adjuvant chemotherapy following primary surgery	0
Adjuvant radiation following primary surgery	0
Adjuvant hormonal therapy following primary surgery	0
Median time to recurrence (months)	
Median (95% CI)	65.7 (0 – 145.6)
Median age at recurrence (range)	46.5 (38.8 – 64.5)
Residual at recurrence surgery	
None	2 (66)
Gross	
<1cm	1 (33)
≥1cm	0 (0)
Adjuvant chemotherapy following recurrence surgery	0
Adjuvant radiation following recurrence surgery	0
Hormonal therapy following recurrence surgery	0
Overall Survival (months)	
Median (95% CI)	NE (NE)

NE – Not Estimable